All News
Filter News
Found 157 articles
-
Longeveron to Participate in the H.C. Wainwright BioConnect 2022 Virtual Conference
1/4/2022
Longeveron Inc. announced that Geoff Green, Chief Executive Officer of Longeveron, will present at the H.C. Wainwright & Co. BioConnect 2022 Virtual Conference, and participate in a panel discussion moderated by Dr. Scott Gottlieb, the former commissioner of the U.S. Food and Drug Administration.
-
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
-
Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)
12/6/2021
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart defect in infants.
-
Longeveron Inc. Announces Closing of a $20.5 Million Private Placement
12/3/2021
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the closing of its previously announced private placement of common stock and warrants.
-
Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement
12/1/2021
Longeveron Inc. announced that it entered into a securities purchase agreement with certain institutional investors to purchase approximately $20.5 million worth of its common stock and warrants in a private placement.
-
Longeveron Announces Phase 2 Clinical Trial in Japan to Test Safety and Efficacy of Lomecel-B on Aging Frailty Patients
11/30/2021
Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced that it has entered into a sponsored clinical research agreement with the National Center for Geriatrics and Gerontology and Juntendo University Hospital in Japan, to explore the safety and efficacy of Lomecel-B in older, frail Japanese subjects.
-
U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition
11/18/2021
Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease designation for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome, a rare and life-threatening congenital heart defect in infants.
-
Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2021 Financial ResultsLongeveron to hold conference call today at 8:30 AM EST
11/12/2021
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), today provided a business update regarding the status of the Company’s various clinical research programs and reported its financial results for the quarter ended September 30, 2021.
-
Clinical Catch-Up: November 1-5
11/8/2021
The first week of November was marked by numerous clinical trial announcements. Here’s a look. -
Longeveron to Release Third Quarter 2021 Financial Results and Hold Conference Call on November 12, 2021
11/8/2021
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its third quarter 2021 financial results on Friday, November 12, 2021 before the open of US markets
-
Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial
11/5/2021
Longeveron Inc. today announced the selection of Biorasi LLC (“Biorasi”) as its clinical research organization (CRO) to help conduct its Phase 2 clinical trial evaluating Lomecel-B infusion in Alzheimer’s Disease (AD) subjects.
-
Clinical Catch-Up: October 18-22
10/25/2021
It was yet another busy week for clinical trial news. Here’s a look. -
Longeveron Announces Activation of Two New Clinical Sites in ELPIS II Trial of Lomecel-B for Hypoplastic Left Heart Syndrome (HLHS)
10/20/2021
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today the activation of two new clinical sites for the currently enrolling ELPIS II Trial, evaluating Lomecel-B injection into the myocardium of infants with Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart defect.
-
Longeveron to Present at the 2021 Dawson James Securities 6th Annual Small Cap Growth Conference
10/14/2021
Longeveron Inc. announced today that Geoff Green, Chief Executive Officer of Longeveron, will present at the Dawson James Small Cap Growth Conference on Thursday, October 21, 2021 at 11:25 a.m. ET in Jupiter, Florida.
-
Longeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity
9/29/2021
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced preliminary top line results from ongoing biomarker analysis from the Company’s Phase 2b trial of Lomecel-B investigational cell therapy in Aging Frailty subjects.
-
Longeveron Announces Multiple Presentations at the 11th Annual International Conference on Frailty & Sarcopenia Research
9/28/2021
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related, and life-threatening conditions, today announced that the Company’s Lomecel-B research program will be featured in two presentations and a roundtable discussion at the 11th Annual International Conference on Frailty & Sarcopenia Research (ICFSR), taking place virtually September 29 - October 2, 2021.
-
Longeveron Announces Dr. Jorge Ruiz as Speaker for Roundtable Discussion & Presentation at 2021 International Conference for Frailty & Sarcopenia Research
9/21/2021
-- Jorge Ruiz, M.D., Associate Director for Clinical Affairs, Geriatric Research at the Miami VA Healthcare System, will present Longeveron’s Aging Frailty Phase 2b Trial Data
-
Longeveron Partners with Kinesiometrics to Create and Implement Cutting-Edge Smart Phone App to Measure Physical Responses to Cell Therapy
9/13/2021
Longeveron Inc. has entered into an agreement with Kinesiometrics Inc., (“Kinesiometrics”) to provide a cutting-edge, digital data-driven solution for objective real-time measurement of functional capacity and quality of life in Longeveron’s clinical studies.
-
Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome Patients
9/9/2021
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the final clinical results from its Phase I clinical study of Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart disease.
-
Longeveron to Present at H.C. Wainwright 23rd Annual Global Investor Conference
9/1/2021
Longeveron Inc. announced today that management will present virtually at the H.C. Wainwright 23rd Annual Global Investor Conference.